10.00

0.60% -0.06

After Hours: 10.00

Embecta Corp (EMBC)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Embecta Corp stock is traded at $10.00, with a volume of 1.45M. It is down -0.60% in the last 24 hours and down -22.18% over the past month. Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Previous Close:

$10.06

Open:

$10.19

24h Volume:

1.45M

Relative Volume:

2.07

Market Cap:

$592.20M

Revenue:

$1.10B

Net Income/Loss:

$83.60M

P/E Ratio:

6.993

EPS:

1.43

Net Cash Flow:

$132.30M

1W Performance:

-4.49%

1M Performance:

-22.18%

6M Performance:

-24.92%

1Y Performance:

-39.83%

1-Day Range:

$9.925

$10.39

1-Week Range:

$9.925

$11.07

52-Week Range:

$9.20

$16.75

Embecta Corp Stock (EMBC) Company Profile

Name

Embecta Corp

Sector

Healthcare (1112)

Industry

Medical Instruments & Supplies (58)

Phone

(862) 401-0000

Address

1209 ORANGE STREET, WILMINGTON

Employee

1,850

Twitter

Next Earnings Date

2025-11-25

Latest SEC Filings

EMBC's Discussions on Twitter

Compare EMBC vs ISRG, BDX, ALC, MDLN, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EMBC Embecta Corp	10.00	595.75M	1.10B	83.60M	132.30M	1.43
ISRG Intuitive Surgical Inc	478.60	176.19B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	177.81	51.41B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	78.55	39.00B	10.19B	1.05B	1.38B	2.1044
MDLN Medline Inc	44.59	37.48B	27.43B	1.27B	1.01B	1.5829
RMD Resmed Inc	245.73	37.82B	5.40B	1.49B	1.78B	10.12

Embecta Corp Stock (EMBC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Mizuho	Neutral
Dec-02-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Nov-27-24	Upgrade	BTIG Research	Neutral → Buy
Oct-20-23	Initiated	Wolfe Research	Peer Perform
Jan-06-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-08-22	Initiated	BTIG Research	Neutral
Aug-01-22	Initiated	Morgan Stanley	Equal-Weight
Jun-21-22	Initiated	BofA Securities	Underperform

View All

Embecta Corp Stock (EMBC) Latest News

01:48 AM

Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively - simplywall.st

01:48 AM

05:47 AM

We Think Embecta's (NASDAQ:EMBC) Solid Earnings Are Understated - Yahoo Finance

05:47 AM

Feb 11, 2026

Embecta names CEO Kurdikar as new board chair, picks new lead independent director - Drug Delivery Business

Feb 11, 2026

Embecta Corp. Appoints Devdatt Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director - Quiver Quantitative

Feb 11, 2026

embecta names new Chairman of the Board and Lead Independent Director - The Manila Times

Feb 11, 2026

embecta CEO Dev Kurdikar adds chair role as Pomeroy becomes lead director - Stock Titan

Feb 11, 2026

Embecta (NASDAQ:EMBC) Is Paying Out A Dividend Of $0.15 - Yahoo Finance

Feb 11, 2026

Feb 10, 2026

Embecta Announces Board Changes, Effective February 11, 2026 - marketscreener.com

Feb 10, 2026

Embecta outlines $1.71B–$1.93B revenue target for 2026 as GLP-1 partnerships gain traction - MSN

Feb 10, 2026

Feb 09, 2026

Embecta (NASDAQ:EMBC) Trading Down 5%Should You Sell? - MarketBeat

Feb 09, 2026

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st

Feb 09, 2026

Embecta Corp. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛

Feb 09, 2026

Why analysts remain bullish on Embecta Corp. stock2025 Earnings Impact & AI Based Buy/Sell Signal Reports - mfd.ru

Feb 09, 2026

Feb 08, 2026

Embecta: Stable Execution, GLP-1–Driven Growth Optionality, and Attractive Valuation Support Buy Rating and $25 Target - TipRanks

Feb 06, 2026

BTIG Research Reiterates "Buy" Rating for Embecta (NASDAQ:EMBC) - MarketBeat

Feb 06, 2026

Embecta Corp. (NASDAQ:EMBC) Q1 2026 Earnings Call Transcript - Insider Monkey

Feb 06, 2026

BTIG Reiterates Buy Rating on Embecta (EMBC) with Stable Price T - GuruFocus

Feb 06, 2026

Embecta Q1 2026 slides: Beats EPS estimates as international growth offsets U.S. decline By Investing.com - Investing.com South Africa

Feb 06, 2026